Argentina’s pharmaceutical landscape
The pharmaceutical landscape in Argentina is characterized by a wide variety of over-the-counter (OTC), and prescription drug categories. These include therapeutic categories such as anti-hypertensive drugs, dermatological drugs, antiviral drugs, and immunosuppressants. In 2022, vaccines were the category with the highest revenue share in the sector, with an estimated 820 million U.S. dollars out of a total of over four billion U.S. dollars for the whole market. Oncology drugs accounted for a similar value, with 650 million U.S. dollars generated that year. Within the OTC segment, skin treatment products, digestive and intestinal remedies, and analgesics were among the main categories.The pharmaceutical company landscape is led by two main Argentinean firms: Roemmers and Elea Phoenix. In 2021, Roemmers held the top spot in the country's pharmaceutical sector in terms of sales revenue and units sold, with a value of roughly 538 million U.S. dollars and 62 million units. Elea Phoenix, came in second with a sales turnover of approximately 497 million U.S. dollars and more than 52 million units sold. The German multinational Bayer, one of the leading pharmaceutical companies in the country when considering corporate reputation, sold a comparable number of units in Argentina that year.